{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:26:26Z","timestamp":1792571186689,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK040561"],"award-info":[{"award-number":["P30 DK040561"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U24 DK132733"],"award-info":[{"award-number":["U24 DK132733"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obstet Gynecol Rep"],"DOI":"10.1007\/s13669-023-00350-1","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T03:03:35Z","timestamp":1677467015000},"page":"138-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pharmacologic Treatment of Obesity in Reproductive Aged Women"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-5052","authenticated-orcid":false,"given":"Akua","family":"Nuako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-6634","authenticated-orcid":false,"given":"Lucy","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-9134","authenticated-orcid":false,"given":"Karen J.","family":"Campoverde Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-5761","authenticated-orcid":false,"given":"Shradha M.","family":"Chhabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-533X","authenticated-orcid":false,"given":"Fatima Cody","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"350_CR1","first-page":"8","volume-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018","author":"CM Hales","year":"2020","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. Centers for Disease Control and Prevention; 2020. p. 8."},{"issue":"25 Pt B","key":"350_CR2","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985\u20133023. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.004.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"350_CR3","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.ijo.0803015","volume":"29","author":"CC Curioni","year":"2005","unstructured":"Curioni CC, Louren\u00e7o PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29(10):1168\u201374. https:\/\/doi.org\/10.1038\/sj.ijo.0803015.","journal-title":"Int J Obes (Lond)"},{"key":"350_CR4","unstructured":"Prescription medications to treat overweight & obesity. https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/prescription-medications-treat-overweight-obesity. Revised June 2021. Accessed 7 Aug\u00a02022."},{"key":"350_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/EdBook_AM.2013.33.e222","author":"PM Webb","year":"2013","unstructured":"Webb PM. Obesity and gynecologic cancer etiology and survival. Am Soc Clin Oncol Educ Book. 2013. https:\/\/doi.org\/10.1200\/EdBook_AM.2013.33.e222.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"350_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5152\/jtgga.2015.15232","volume":"16","author":"ZO Dag","year":"2015","unstructured":"Dag ZO, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111\u20137. https:\/\/doi.org\/10.5152\/jtgga.2015.15232.","journal-title":"J Turk Ger Gynecol Assoc"},{"issue":"8","key":"350_CR7","doi-asserted-by":"publisher","first-page":"e0202183","DOI":"10.1371\/journal.pone.0202183","volume":"13","author":"C Chen","year":"2018","unstructured":"Chen C, Xu X, Yan Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. PLoS One. 2018;13(8):e0202183. https:\/\/doi.org\/10.1371\/journal.pone.0202183.","journal-title":"PLoS One"},{"issue":"6","key":"350_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/AOG.0000000000004395","volume":"137","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice, Bulletins-Obstetrics","year":"2021","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice, Bulletins-Obstetrics. Obesity in Pregnancy: ACOG Practice Bulletin, Number 230. Obstet Gynecol. 2021;137(6):128\u201344. https:\/\/doi.org\/10.1097\/AOG.0000000000004395.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"350_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.2020.21096","volume":"325","author":"SM Ogunwole","year":"2021","unstructured":"Ogunwole SM, Zera CA, Stanford FC. Obesity management in women of reproductive age. JAMA. 2021;325(5):433\u20134. https:\/\/doi.org\/10.1001\/jama.2020.21096.","journal-title":"JAMA"},{"key":"350_CR10","volume-title":"FDA approves new drug treatment for chronic weight management, first since 2014","author":"Administration USFaD","year":"2021","unstructured":"FDA approves new drug treatment for chronic weight management, first since 2014. FDA. Washington, DC: Center for Drug Evaluation and Research. June 2021."},{"key":"350_CR11","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med.\u00a02021."},{"key":"350_CR12","volume-title":"Translational Metabolic Syndrome Research","author":"K Alabduljabbar","year":"2022","unstructured":"Alabduljabbar K, Vincent RP, le Roux CW. Semaglutide is precipitating a revolution in obesity care. In: Translational Metabolic Syndrome Research. Elsevier; 2022."},{"key":"350_CR13","unstructured":"WEGOVY (semaglutide injection) for subcutaneous use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf. Revised June 2021. Accessed 8 Aug\u00a02022."},{"issue":"2","key":"350_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"9","key":"350_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMc1615712","volume":"376","author":"SP Marso","year":"2017","unstructured":"Marso SP, Holst AG, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891\u20132. https:\/\/doi.org\/10.1056\/NEJMc1615712.","journal-title":"N Engl J Med"},{"issue":"1","key":"350_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"key":"350_CR17","unstructured":"SAXENDA (liraglutide injection) for subcutaneous use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206321s007lbl.pdf. Revised October 2018. Accessed 8 Aug\u00a02022."},{"issue":"1","key":"350_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Bokal EV. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1\u201311.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"350_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","volume":"35","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121\u20137.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"350_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacother J Hum Pharmacol Drug Ther. 2000;20(3):270\u20139.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"2","key":"350_CR21","first-page":"95","volume":"5","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Clin Diabetol. 2004;5(2):95\u2013104.","journal-title":"Clin Diabetol"},{"key":"350_CR22","unstructured":"XENICAL (orlistat) capsule. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020766s029lbl.pdf. Revised January 2012. Accessed 7 Aug\u00a02022."},{"issue":"1","key":"350_CR23","first-page":"135","volume":"102","author":"KH Saunders","year":"2018","unstructured":"Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin. 2018;102(1):135\u201348.","journal-title":"Med Clin"},{"key":"350_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","volume":"92","author":"E Pilitsi","year":"2019","unstructured":"Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou A-E, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2019;92:170\u201392.","journal-title":"Metabolism"},{"issue":"2","key":"350_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0002-9149(01)02208-1","volume":"89","author":"AS Wierzbicki","year":"2002","unstructured":"Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol. 2002;89(2):229\u201331. https:\/\/doi.org\/10.1016\/s0002-9149(01)02208-1.","journal-title":"Am J Cardiol"},{"key":"350_CR26","unstructured":"Qsymia (phentermine and topiramate extended-release) capsules. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022580s021lbl.pdf. Revised June 2022. Accessed 9 Aug\u00a02022."},{"issue":"22","key":"350_CR27","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424\u201334.","journal-title":"JAMA"},{"issue":"5","key":"350_CR28","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/j.1467-789x.2010.00846.x","volume":"12","author":"CK Kramer","year":"2011","unstructured":"Kramer CK, Leit\u00e3o CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338\u201347. https:\/\/doi.org\/10.1111\/j.1467-789x.2010.00846.x.","journal-title":"Obes Rev"},{"key":"350_CR29","unstructured":"Topamax (topiramate) tablets for oral use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020505s062,020844s053lbl.pdf. Revised January 2022. Accessed 9 June\u00a02022."},{"key":"350_CR30","unstructured":"CONTRAVE (naltrexone HCl and bupropion HCl) extended release tablet. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022580s021lbl.pdf. Revised September 2014. Accessed 9 Aug\u00a02022."},{"issue":"10077","key":"350_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Le Roux","year":"2017","unstructured":"Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"9","key":"350_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/oby.2001.71","volume":"9","author":"KM Gadde","year":"2001","unstructured":"Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9(9):544\u201351.","journal-title":"Obes Res"},{"issue":"1","key":"350_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tem.2021.10.005","volume":"33","author":"S Fulton","year":"2022","unstructured":"Fulton S, D\u00e9carie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 2022;33(1):18\u201335.","journal-title":"Trends Endocrinol Metab"},{"key":"350_CR34","unstructured":"Wellbutrin (bupropion hydrochloride) tablets. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/018644s054lbl.pdf. Accessed 9 June\u00a02022."},{"key":"350_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"350_CR36","unstructured":"MOUNJARO (tirzepatide) injection for subcutaneous use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Revised May 2022. Accessed 9 Aug\u00a02022."},{"issue":"3","key":"350_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2337\/cd20-0032","volume":"38","author":"N Giruzzi","year":"2020","unstructured":"Giruzzi N. Plenity (Oral Superabsorbent Hydrogel). Clin Diabetes. 2020;38(3):313\u20134. https:\/\/doi.org\/10.2337\/cd20-0032.","journal-title":"Clin Diabetes"},{"issue":"2","key":"350_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/oby.22347","volume":"27","author":"FL Greenway","year":"2019","unstructured":"Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring). 2019;27(2):205\u201316. https:\/\/doi.org\/10.1002\/oby.22347.","journal-title":"Obesity (Silver Spring)"},{"key":"350_CR39","first-page":"72","volume":"7","author":"\u0218 St\u0103cescu","year":"2019","unstructured":"St\u0103cescu \u0218, Hancu G, Podar D, Todea \u0218, Tero-Vescan A. A historical overview upon the use of amphetamine derivatives in the treatment of obesity. J Pharm Care. 2019;7:72\u20139.","journal-title":"J Pharm Care"},{"issue":"1","key":"350_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4093\/dmj.2012.36.1.13","volume":"36","author":"JG Kang","year":"2012","unstructured":"Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36(1):13\u201325. https:\/\/doi.org\/10.4093\/dmj.2012.36.1.13.","journal-title":"Diabetes Metab J"},{"key":"350_CR41","unstructured":"Lists of scheduling actions, controlled substances, regulated chemicals. In: U.S. Department of Justice DEA, Diversion Control Division, Drug & Chemical Evaluation Section, U.S. Department of Justice; Revised January 2023. Accessed January 18, 2023."},{"key":"350_CR42","doi-asserted-by":"crossref","unstructured":"\u2022 Choi EJ, Han JY. Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy. Clin Exp Obstet Gynecol. 2021;48(3):514\u201322. This study is unique in that it followed pregnancy outcomes for a large group of human women (~30,000) who were inadvertently exposed to AOMs such as phentermine during pregnancy. The vast majority of studies related to human pregnancy and anti-obesity pharmacotherapy contain a very small number of subjects due to ethics concerns. This study provided a unique opportunity to observe natural data on this topic in a manner that mitigated some related ethics concerns.","DOI":"10.31083\/j.ceog.2021.03.2331"},{"key":"350_CR43","unstructured":"Fendique ER (phendimetrazine tartrate) extended release capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/018074Orig1s037lbl.pdf. Revised November 2020. Accessed 9 June\u00a02022."},{"key":"350_CR44","unstructured":"Adipex-P (phentermine) capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/085128s065lbl.pdf. Revised April 2012. Accessed 9 June\u00a02022."},{"key":"350_CR45","unstructured":"Tenuate (diethylpropion hydrochloride USP) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/11722s029,12546s032lbl.pdf. Revised November 2003. Accessed 9 June\u00a02022."},{"key":"350_CR46","unstructured":"Didrex (benzphetamine hydrochloride) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/012427s031lbl.pdf. Revised April 2020. Accessed 9 June\u00a02022."},{"key":"350_CR47","unstructured":"Glucophage (metformin hydrochloride) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020357s037s039,021202s021s023lbl.pdf. Revised April 2017. Accessed 9 June\u00a02022."},{"issue":"18","key":"350_CR48","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40265-018-1025-0","volume":"78","author":"YE Lentferink","year":"2018","unstructured":"Lentferink YE, Knibbe CAJ, Van Der Vorst MMJ. Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review. Drugs. 2018;78(18):1887\u2013901. https:\/\/doi.org\/10.1007\/s40265-018-1025-0.","journal-title":"Drugs"},{"issue":"7","key":"350_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/bdr2.1199","volume":"110","author":"S Dukhovny","year":"2018","unstructured":"Dukhovny S, Van Bennekom CM, Gagnon DR, Hernandez Diaz S, Parker SE, Anderka M, et al. Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. Birth Defects Research. 2018;110(7):579\u201386. https:\/\/doi.org\/10.1002\/bdr2.1199.","journal-title":"Birth Defects Research"},{"key":"350_CR50","unstructured":"Metformin. Drugs and Lactation Database (LactMed(R)). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501020\/. Revised March 2022. Accessed 18 Jan\u00a02023."},{"issue":"2","key":"350_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0890334418819465","volume":"35","author":"L Nommsen-Rivers","year":"2019","unstructured":"Nommsen-Rivers L, Thompson A, Riddle S, Ward L, Wagner E, King E. Feasibility and acceptability of metformin to augment low milk supply: a pilot randomized controlled trial. J Hum Lact. 2019;35(2):261\u201371. https:\/\/doi.org\/10.1177\/0890334418819465.","journal-title":"J Hum Lact"},{"issue":"11","key":"350_CR52","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1471-0528.2012.03449.x","volume":"119","author":"E Vanky","year":"2012","unstructured":"Vanky E, Nordskar JJ, Leithe H, Hjorth-Hansen AK, Martinussen M, Carlsen SM. Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. BJOG. 2012;119(11):1403\u20139. https:\/\/doi.org\/10.1111\/j.1471-0528.2012.03449.x.","journal-title":"BJOG"},{"key":"350_CR53","unstructured":"Invokana (canagliflozin) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204042s034lbl.pdf. Revised August 2020. Accessed 9 June\u00a02022."},{"issue":"1","key":"350_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","volume":"30","author":"AJY Cheong","year":"2022","unstructured":"Cheong AJY, Teo YN, Teo YH, Syn NL, Ong HT, Ting AZ, et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity. 2022;30(1):117\u201328.","journal-title":"Obesity"},{"issue":"14","key":"350_CR55","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","volume":"289","author":"KM Gadde","year":"2003","unstructured":"Gadde KM, Franciscy DM, Wagner Ii HR, Krishnan KRR. Zonisamide for weight loss in obese adults. JAMA. 2003;289(14):1820. https:\/\/doi.org\/10.1001\/jama.289.14.1820.","journal-title":"JAMA"},{"issue":"20","key":"350_CR56","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/2013.jamainternmed.99","volume":"172","author":"KM Gadde","year":"2012","unstructured":"Gadde KM, Kopping MF, Wagner HR, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012;172(20):1557\u201364.","journal-title":"Arch Intern Med"},{"key":"350_CR57","unstructured":"Zonisamide. Drugs and Lactation Database (LactMed(R)). Revised September 2020. Accessed January 18, 2023."},{"key":"350_CR58","unstructured":"Zonegran (zonisamide) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020789s036lbl.pdf. Revised April 2020. Accessed 9 June\u00a02022."},{"issue":"8","key":"350_CR59","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1210\/jc.2006-2003","volume":"92","author":"L Aronne","year":"2007","unstructured":"Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"350_CR60","unstructured":"Symlin (pramlintide acetate) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021332s028lbl.pdf. Revised December 2019. Accessed 9 June\u00a02022."},{"issue":"9","key":"350_CR61","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"SR Smith","year":"2008","unstructured":"Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816\u201323.","journal-title":"Diabetes Care"},{"issue":"4","key":"350_CR62","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7570\/jomes21071","volume":"30","author":"B Dehestani","year":"2021","unstructured":"Dehestani B, Stratford NR, le Roux CW. Amylin as a future obesity treatment. J Obes Metab Syndr. 2021;30(4):320.","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"350_CR63","doi-asserted-by":"publisher","first-page":"205510291875969","DOI":"10.1177\/2055102918759691","volume":"5","author":"KM Sattler","year":"2018","unstructured":"Sattler KM, Deane FP, Tapsell L, Kelly PJ. Gender differences in the relationship of weight-based stigmatisation with motivation to exercise and physical activity in overweight individuals. Health Psychol Open. 2018;5(1):2055102918759691. https:\/\/doi.org\/10.1177\/2055102918759691.","journal-title":"Health Psychol Open"},{"issue":"3","key":"350_CR64","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/j.fertnstert.2019.07.1082","volume":"112","author":"AK Worthington","year":"2019","unstructured":"Worthington AK, Burke EE, Leahy C. A comprehensive examination of infertility stigma among fertile and infertile women in the United States. Fertil Steril. 2019;112(3):e378. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.07.1082.","journal-title":"Fertil Steril"}],"container-title":["Current Obstetrics and Gynecology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13669-023-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13669-023-00350-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13669-023-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T03:47:49Z","timestamp":1686282469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13669-023-00350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s13669-023-00350-1","relation":{},"ISSN":["2161-3303"],"issn-type":[{"value":"2161-3303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"31 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors don\u2019t have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}